CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price
on Jun 23, 2023
CTI BioPharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CTI BioPharma stock had an average target of 9.80, with a low estimate of 8.00 and a high estimate of 13.
Analyst Consensus: Buy
* Price targets were last updated on May 16, 2023.
Analyst Ratings
The average analyst rating for CTI BioPharma stock from 6 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 24, 2023 |
| SVB Leerink | SVB Leerink | Buy → Hold Downgrades $13 → $9.1 | Buy → Hold | Downgrades | $13 → $9.1 | +0.11% | May 16, 2023 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $8.1 → $9.1 | Strong Buy → Hold | Downgrades | $8.1 → $9.1 | +0.11% | May 15, 2023 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 11, 2023 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 11, 2023 |
Financial Forecast
Revenue This Year
127.10M
from 53.95M
Increased by 135.60%
Revenue Next Year
257.94M
from 127.10M
Increased by 102.94%
EPS This Year
-0.28
from -0.81
EPS Next Year
0.40
from -0.28
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 146.6M | 396.2M | 443.7M | ||
| Avg | 127.1M | 257.9M | 345.6M | ||
| Low | 92.8M | 142.0M | 210.4M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 171.7% | 211.7% | 72.0% | ||
| Avg | 135.6% | 102.9% | 34.0% | ||
| Low | 72.0% | 11.7% | -18.4% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -0.13 | 1.01 | 1.41 | ||
| Avg | -0.28 | 0.40 | 0.67 | ||
| Low | -0.48 | -0.19 | 0.09 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | 247.7% | ||
| Avg | - | - | 64.9% | ||
| Low | - | - | -78.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.